Abstract
The sinovial sarcoma is a malignant mesenchyma. Although sarcomas are a rare disease, they account for approximately 1% of the total tumors, and are responsible for 2% of cancer mortality. This represents between 5 and 10% of all soft tissue sarcomas, and is the fourth frequency, after malignant fibrous histiocytoma, liposarcoma and rhabdomyosarcoma. The objective of this study is to estimate the total medical cost of illness of Synovial Sarcoma at the National Institute of Cancerology (Mexico City), in the last 10 years (2010-2021).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.